Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • Editorial Board
    • Meet the Editors
    • Editorial Manifesto
    • Impact Factor
    • Journal History
    • General Statistics
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • Circulation Research Profiles
    • Trainees & Young Investigators
    • Research Around the World
    • News & Views
    • The NHLBI Page
    • Viewpoints
    • Compendia
    • Reviews
    • Recent Review Series
    • Profiles in Cardiovascular Science
    • Leaders in Cardiovascular Science
    • Commentaries on Cutting Edge Science
    • AHA/BCVS Scientific Statements
    • Abstract Supplements
    • Circulation Research Classics
    • In This Issue Archive
    • Anthology of Images
  • Resources
    • Online Submission/Peer Review
    • Why Submit to Circulation Research
    • Instructions for Authors
    • → Article Types
    • → Manuscript Preparation
    • → Submission Tips
    • → Journal Policies
    • Circulation Research Awards
    • Image Gallery
    • Council on Basic Cardiovascular Sciences
    • Customer Service & Ordering Info
    • International Users
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Impact Factor 13.965
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Circulation Research

  • My alerts
  • Sign In
  • Join

  • Impact Factor 13.965
  • Facebook
  • Twitter
  • Home
  • About this Journal
    • Editorial Board
    • Meet the Editors
    • Editorial Manifesto
    • Impact Factor
    • Journal History
    • General Statistics
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • Circulation Research Profiles
    • Trainees & Young Investigators
    • Research Around the World
    • News & Views
    • The NHLBI Page
    • Viewpoints
    • Compendia
    • Reviews
    • Recent Review Series
    • Profiles in Cardiovascular Science
    • Leaders in Cardiovascular Science
    • Commentaries on Cutting Edge Science
    • AHA/BCVS Scientific Statements
    • Abstract Supplements
    • Circulation Research Classics
    • In This Issue Archive
    • Anthology of Images
  • Resources
    • Online Submission/Peer Review
    • Why Submit to Circulation Research
    • Instructions for Authors
    • → Article Types
    • → Manuscript Preparation
    • → Submission Tips
    • → Journal Policies
    • Circulation Research Awards
    • Image Gallery
    • Council on Basic Cardiovascular Sciences
    • Customer Service & Ordering Info
    • International Users
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Integrative Physiology

CIB1 Regulates Endothelial Cells and Ischemia-Induced Pathological and Adaptive Angiogenesis

Mohamed A. Zayed, Weiping Yuan, Tina M. Leisner, Dan Chalothorn, Andrew W. McFadden, Michael D. Schaller, M. Elizabeth Hartnett, James E. Faber, Leslie V. Parise
Download PDF
https://doi.org/10.1161/CIRCRESAHA.107.157586
Circulation Research. 2007;101:1185-1193
Originally published November 26, 2007
Mohamed A. Zayed
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Weiping Yuan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tina M. Leisner
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dan Chalothorn
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew W. McFadden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael D. Schaller
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Elizabeth Hartnett
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James E. Faber
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leslie V. Parise
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Supplemental Materials
  • Info & Metrics

Jump to

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Tables
  • Supplemental Materials
  • Info & Metrics
  • eLetters
Loading

Abstract

Pathological angiogenesis contributes to various ocular, malignant, and inflammatory disorders, emphasizing the need to understand this process on a molecular level. CIB1 (calcium- and integrin-binding protein), a 22-kDa EF-hand–containing protein, modulates the activity of p21-activated kinase 1 in fibroblasts. Because p21-activated kinase 1 also contributes to endothelial cell function, we hypothesized that CIB1 may have a role in angiogenesis. We found that endothelial cells depleted of CIB1 by either short hairpin RNA or homologous recombination have reduced migration, proliferation, and tubule formation. Moreover, loss of CIB1 in these cells decreases p21-activated kinase 1 activation, downstream extracellular signal-regulated kinase 1/2 activation, and matrix metalloproteinase 2 expression, all of which are known to contribute to angiogenesis. Consistent with these findings, tissues derived from CIB1-deficient (CIB1−/−) mice have reduced growth factor–induced microvessel sprouting in ex vivo organ cultures and in vivo Matrigel plugs. Furthermore, in response to ischemia, CIB1−/− mice demonstrate decreased pathological retinal and adaptive hindlimb angiogenesis. Ischemic CIB1−/− hindlimbs also demonstrate increased tissue damage and significantly reduced p21-activated kinase 1 activation. These data therefore reveal a critical role for CIB1 in ischemia-induced pathological and adaptive angiogenesis.

  • angiogenesis
  • endothelial cells
  • ischemia
  • CIB1
  • PAK1

Ischemia-induced angiogenesis involves both pathological and adaptive angiogenesis and has a clear association with many disorders that involve various types of human tissue.1 In ischemic retinal diseases, such as diabetic retinopathy, retinopathy of prematurity, and age-related macular degeneration, angiogenesis is excessive; the goal in these retinal diseases is to inhibit ischemia-induced pathological angiogenesis.2–4 Alternatively, in ischemic diseases, such as peripheral vascular disease and ischemic heart disease, the induction of adaptive angiogenesis is beneficial in preventing tissue damage and promoting recovery.5 Central to this process are vascular endothelial cells (ECs), which respond to both anti- and proangiogenic factors and on activation, undergo a remarkable increase in migration, proliferation, nascent tubule formation, and matrix metalloproteinase (MMP) secretion.6,7 Identifying exactly which molecules contribute to these processes, but not to physiological angiogenesis (angiogenesis during development and tissue regeneration), will provide better therapeutic targets to alleviate ischemia-associated diseases and aid in our understanding of how pathological angiogenesis arises.

CIB1 (also known as calmyrin or kinase-interacting protein [KIP]) is a 22-kDa EF-hand–containing protein identified originally in a yeast 2-hybrid screen as a binding partner for the cytoplasmic tail of the platelet integrin αIIb.8 It was later determined that CIB1 inhibits agonist-induced αIIbβ3 activation in megakaryocytes.9 However, CIB1 is widely distributed, suggesting that it has cellular functions independent of αIIbβ3.10 Accordingly, CIB1 appears to regulate various cellular processes by associating with proteins such as the Alzheimer’s disease associated presenilin-2,11 the inositol 1,4,5-triphosphate receptor,12 focal adhesion kinase (FAK),13 and p21-activated kinase (PAK)1.14 Among these binding partners, FAK and PAK1 are known to regulate EC function and in vivo angiogenesis.15,16

We recently engineered a CIB1-deficient (CIB1−/−) mouse via homologous recombination in embryonic stem cells. Although CIB1−/− mice reach all developmental milestones, adult male mice are sterile because of a defect in the haploid phase of spermatogenesis.17 Here we demonstrate that loss of CIB1 attenuates PAK1 and extracellular signal-regulated kinase (ERK)1/2 activation and MMP-2 expression. We also demonstrate that CIB1 is critical for various EC functions and that CIB1−/− mice have significant defects in growth factor- and ischemia-induced pathological and adaptive angiogenesis. Therefore, our studies identify CIB1 as a target for therapy in angiogenesis-dependent clinical disorders.

Materials and Methods

Reagents, Cells, and Short Hairpin RNA Construction

All reagents, cell types, blotting techniques, and short hairpin (sh)RNA construction are described in the online data supplement at http://circres.ahajournals.org.

Boyden Chamber Haptotactic, Matrigel Tubule Formation, and ELISA Assays

Haptotactic migration and tubule formation were performed as described previously with minor modifications.14 These assays and ELISA proliferation assays are described in the online data supplement.

PAK1 Kinase Activation Assay

Lysates of fibronectin-adherent ECs or ischemic and nonischemic gastrocnemius muscles were prepared by addition of cold lysis buffer, supplemented with 10% glycerol and 0.2 mmol/L pervanadate. Kinase assays were performed as described previously.14,18 For each experiments, n=3.

Gelatin Zymography

The activity of MMP-2 in conditioned media was determined by gelatin zymography. Briefly, ECs were serum starved for at least 24 hours, followed by addition of phenol-free basal medium supplemented with 100 ng/mL of growth factor. After 18 hours, conditioned media were collected, filtered through 0.45-μm Whatman filters, and concentrated using a Vivaspin 10-kDa concentrator (Sartorius, Edgewood, NY). Equal protein concentrations were loaded under nonreducing conditions onto premade 10% zymograms and developed according to the instructions of the manufacture (Bio-Rad, Hercules, Calif). For each experiment, n=3.

Ex Vivo Tissue Cultures

Tissue culturing was performed as described previously with minor modifications.19,20 Wild-type (WT) and CIB1−/− aortic rings were embedded between 2 layers of 250 μL of growth factor–reduced Matrigel in a 24-well culture format and cultured in 300 μL of growth media or basal media supplemented with 50 ng/mL basic fibroblast growth factor (bFGF) or vascular endothelial growth factor (VEGF). At 2, 5, and 8 days, images of aortic rings were collected and stitched together using PhotoFit Premium software (Tekmate, Tokyo, Japan). At each time point, the total number of sprouting microvessels were counted using ImageJ as described previously19 (n=8 per group). Identical procedures were used for the tibialis anterior muscle cultures and were analyzed in a similar manner after 8 days of culturing.

In Vivo Matrigel Plug Assay

Matrigel plug assays were performed as described previously,21 with minor modifications. WT and CIB1−/− mice were subcutaneously injected with ≈300 μL of growth factor–reduced Matrigel mixed with 60 U/mL heparin or with heparin plus 250 ng/mL bFGF or VEGF. After 14 days, plugs were isolated along with adjacent skin and peritoneal muscle, fixed, and sectioned at interrupted intervals. Blood vessel infiltration was analyzed in 4 random hematotoxin/eosin (H&E)-stained interrupted sections using a Nikon inverted microscope and expressed as mean values of infiltrating blood vessels per plug (n=3 per group).

Oxygen-Induced Retinal Angiogenesis Assay

Postnatal day 7 (P7) mice were placed in 75% oxygen for 5 days. Following hyperoxic incubation, P12 CIB1−/− and WT neonatal mice were housed for 5 additional days under normoxic conditions, after which P17 mouse eyeballs were fixed in 2% paraformaldehyde and either microdissected to obtain retinal flat mounts or cryopreserved in OCT (IMEB, San Marcos, Calif). Fluorescent images of flat mounts stained with Alexa594-conjugated Griffonia simplicifolia isolectin B4 (isolectin GSL-1-B4; 1:100, Invitrogen) were analyzed with a Nikon inverted microscope (PhotoFit, TekMate, Anchorage, Alaska; ImageJ; n=8 mice per group). Interrupted 6-μm sections at 50-μm intervals were obtained for cryopreserved eyeballs and H&E stained. Mean capillary area of vessels either directly under or invading the retinal inner limiting membrane (ILM) were measured from digitized images obtained from 2 randomly selected interrupted eyeball sections (n=4 mice per group).

Unilateral Femoral Artery Ligation, Laser Doppler Perfusion Imaging, and Appearance and Use Score Assessments

Ligation, imaging, and use scores were performed as described previously.22,23 Appearance scores were based on the scale; 0=no change; 1 to 5=the number of discolored/lost nails; and 6 to 10=the number of discolored/lost digits (n=11 mice per group).

Atrophy and Capillary Density in Gastrocnemius Muscles

Twenty-one days after femoral artery ligation, gastrocnemius muscles were fixed and paraffin embedded as described previously.22 For each sample, 5 sections (50 μm apart) were obtained and stained with H&E or Masson’s trichrome or labeled with isolectin GSL-1-B4 (1:100). Three 20× images were collected for each condition from 2 randomly selected sections. Using ImageJ, muscle atrophy and capillary density were estimated as described previously (n=5–9 mice per group).22

Animal Regulations

All housing, breeding, and experimental procedures with mice were in accordance with national guidelines and regulations, and were approved by the University of North Carolina at Chapel Hill Institutional Animal Care and Use Committee.

Statistical Analysis

Continuous variables were compared with either the Student’s t test or nonparametric Mann–Whitney U test. We considered P<0.05 to be significant. For animal studies, male and female mice demonstrated no experimental differences; thus they were combined.

Results

Loss of CIB1 Disrupts Normal EC Function

CIB1 is expressed in highly vascularized adult mouse organs, embryonic vascular structures, and ECs (Figure I in the online data supplement). Because CIB1 associates with angiogenic kinases such as PAK114 and FAK,13 we hypothesized that CIB1 may contribute to EC function. We first tested the role of CIB1 in EC migration using a conventional Boyden chamber haptotactic migration assay.14 Knockdown of CIB1 with shRNA (supplemental Figures II and III) decreased haptotaxis of immortalized mouse embryonic heart ECs (MECs) on fibronectin (38% relative to control MECs; Figure 1A). Similar results were also obtained in the presence of actinomycin D, demonstrating that the haptotactic assay was not significantly influenced by EC proliferation during the relatively short period of this assay (data not shown). Similarly, mouse lung ECs (MLECs) isolated from CIB1−/− mice demonstrated a similar decrease in migration (24% decrease relative to WT and CIB1+/− MLECs; Figure 1B). Although angiogenic growth factors bFGF and VEGF increased haptotaxis in untransduced MECs (data not shown) and control transduced MECs, they did not rescue haptotaxis in CIB1 knockdown MECs (Figure 1A). Interestingly, reintroduction of CIB1 in CIB1−/− MLECs restored haptotactic migration up to, but not beyond, normal levels (Figure 1B). To confirm these findings, we also tested the role of CIB1 in EC migration using a monolayer wound-healing assay. Monolayer wounds in both CIB1-depleted MECs and CIB1−/− mouse heart ECs (MHECs) resolved less rapidly, relative to control transduced MECs and WT MHECs, respectively (supplemental Figure IV). Therefore, these data demonstrate that CIB1 expression is necessary for normal EC migration.

Figure1
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 1. Loss of CIB1 decreases EC function. A, Boyden chamber migration assays of MECs transduced with CIB1 shRNA or control shRNA toward fibronectin in the presence or absence of bFGF or VEGF. B, Haptotactic migration of MLECs either untransduced or transduced with control cDNA or CIB1 cDNA vectors. C, Quantification of BrdUrd incorporation as the fold difference in absorbance (optical density [OD]370) of MECs cultured either in growth media or basal media supplemented with bFGF or VEGF. D, Fold change in BrdUrd incorporation in CIB1−/− and WT MHECs and MLECs cultured in growth media. E, Differential interference contrast (DIC) and green fluorescent protein fluorescent images of CIB1 shRNA-transduced MECs and control shRNA-transduced MECs following treatment with growth media, bFGF, or VEGF. Green fluorescent protein images confirm MEC transduction and expression of vectors. Scale bars, 100 μm. F, Quantification of tubule formation in CIB1−/− and WT MHECs following treatment with growth media, bFGF, or VEGF. Error bars represent SEM (n=at least 3 for all assays and conditions). *P<0.05, **P<0.001.

Proliferation of ECs is also fundamental to angiogenesis.6 Relative to control, MECs depleted of CIB1 by shRNA and cultured in either growth media or basal media supplemented with either bFGF or VEGF demonstrated modest yet significantly decreased 5-bromodeoxyuridine (BrdUrd) incorporation (Figure 1C). No difference in proliferation between untransduced and control transduced MECs was observed (data not shown). Consistent with this, CIB1−/− MHECs and MLECs cultured in growth media also demonstrated a 61% and 35% decrease, respectively, in BrdUrd incorporation compared with WT ECs (Figure 1D). Direct cell counts of cultured CIB1-depleted MECs and CIB1−/− MHECs further confirmed a significant decrease in proliferation relative to controls (data not shown). Thus, in addition to migration, CIB1 is also necessary for normal rates of EC proliferation.

To determine whether loss of CIB1 affects other EC functions, we also assessed tubule formation on growth factor–reduced Matrigel. In the presence of growth media, CIB1-depleted MECs and CIB1−/− MHECs showed a 26% and 44% reduction in nascent tubule formation compared with their respective controls (Figure 1E and 1F). Treatment of CIB1-depleted MECs and CIB1−/− MHECs with bFGF or VEGF did not stimulate tubule formation to the same extent as control cells (Figure 1E and 1F). Hence, in addition to EC migration and proliferation, CIB1 appears to be required for efficient EC sprouting and invasion, events required for angiogenesis.

Loss of CIB1 in ECs Disrupts PAK1 and ERK1/2 Activation

We previously determined that CIB1 regulates PAK1 activation in fibroblasts and transformed epithelial cells.14 Naik and Naik also have reported that CIB1 can regulate FAK activation.13 Because several studies have underscored the importance of PAK1, FAK, and their downstream mitogen-activated protein kinase (MAPK) effectors, ERK1/2 and p38, in EC angiogenic signaling,15,16,24 we asked whether loss of CIB1 affects the activation of these signaling molecules. Although FAK phosphorylation was not significantly altered in CIB1−/− ECs (data not shown), in vitro kinase assays revealed significantly less active PAK1 in CIB1−/− MLECs relative to control cells, 20 and 45 minutes following adhesion to fibronectin (Figure 2A). Decreased PAK1 activation was also observed in CIB1-depleted MECs (data not shown). Similarly, decreased ERK1/2 phosphorylation was observed in CIB1−/− MLECs, without changes in total ERK1/2 protein levels, 20 and 45 minutes following adhesion (Figure 2B). Control ECs also showed differences in the relative peak activation times of PAK1 and ERK1/2, suggesting the contribution of additional signaling pathways leading to ERK1/2 activation. However, despite these differences, we consistently found decreased activation of both PAK1 and ERK1/2 in CIB1−/− ECs. Importantly, no differences in protein kinase C and p38 MAPK phosphorylation were detected in WT and CIB1−/− MLECs following adhesion (Figure 2B and data not shown). Thus, these data demonstrate that loss of CIB1 can disrupt EC signaling, potentially via regulation of PAK1 and ERK1/2 activation in ECs.

Figure2
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 2. Loss of CIB1 disrupts PAK1 activation and MMP-2 expression. A, PAK1 activity in WT and CIB1−/− MLECs held in suspension or adhered to fibronectin for the indicated times. PAK1 in vitro kinase assays were performed using myelin basic protein as substrate ([32P]MBP). Western blots of total PAK1 protein and Coomassie stain of myelin basic protein serve as loading controls. B, Thr514 protein kinase C (PKC) and ERK1/2 phosphorylation in WT and CIB1−/− MLECs held in suspension or adhered to fibronectin. Western blots of total ERK1/2 and Rac serve as loading controls. C, Conditioned media of growth factor–treated and untreated WT and CIB1−/− MLECs were subjected to gelatin zymography. Clear bands in destained gel represent MMP-2. D, Western blot of MMP-2 in conditioned media of growth factor–treated and untreated WT and CIB1−/− MLECs. For C and D, Coomassie-stained nonspecific bands serve as loading controls. E, Western blot of total MMP-2 and CIB1 protein in duplicate WT and CIB1−/− MHEC lysates. Blot for GAPDH serves as a loading control. For each experiment, n=3.

Loss of CIB1 in ECs Decreases MMP-2 Expression

Numerous signaling cascades can be activated downstream of PAK1.25 Among them are MAPKs that are implicated in the production and activation of MMPs.26 Because loss of CIB1 in ECs resulted in decreased responsiveness to angiogenic growth factors and decreased PAK1 and ERK1/2 activation on adhesion to fibronectin, we asked whether MMP expression was also affected. Enzymatic activity of MMPs was assessed by gelatin zymography, which revealed increased lytic zones only at the molecular mass of MMP-2 (68 kDa) in the conditioned media of growth factor–treated WT MLECs but not CIB1−/− MLECs (Figure 2C). Western blotting also demonstrated less growth factor–induced MMP-2 expression in CIB1−/− MLEC conditioned media (Figure 2D), and decreased MMP-2 protein expression in lysates derived from CIB1−/− MHECs (Figure 2E). However, MMP-9 secretion was undetectable in WT and CIB1−/− ECs (data not shown). Furthermore, WT and CIB1−/− ECs showed no differences in the expression of the physiological inhibitor (tissue inhibitor of metalloproteinases [TIMP]-227) and activator of MMP-2, (MMP-14 [MT1-MMP]27) (data not shown).

CIB1 Deficiency Diminishes bFGF and VEGF-Induced Microvessel Growth

The decreased response to bFGF and VEGF and attenuated MMP-2 expression by CIB1−/− ECs led us to ask whether angiogenesis is decreased ex vivo, in cultured microsections of aortas and tibialis anterior muscles from CIB1−/− mice. CIB1−/− aortic rings and tibialis anterior muscles cultured for 8 days in growth media produced ≈50% fewer microvessels, relative to control (Figure 3A through 3C). In addition, CIB1−/− aortic rings also produced ≈60% fewer microvessels in response to bFGF and VEGF (Figure 3A and 3B). We further assessed growth factor–induced angiogenesis in vivo by implanting WT and CIB1−/− mice with Matrigel plugs impregnated with bFGF or VEGF. Microvessel infiltration into the plugs was reduced by ≈80% in CIB1−/− mice compared with WT littermates (Figure 3D and 3E). Thus, growth factor–induced angiogenesis is strongly inhibited in CIB1−/− mice.

Figure3
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 3. Reduced growth factor–induced microvessel sprouting in CIB1−/− tissue. A, Low-magnification DIC images of WT and CIB1−/− ex vivo aortic ring cultures show newly formed microvessels 8 days following treatment with growth media, bFGF, or VEGF. Scale bar, 0.2 mm. B, Quantification of microvessel sprouts of WT and CIB1−/− aortic rings cultured in growth media or growth factor–supplemented basal media. Error bars are ±SEM (replicates of at least 4; n=6 to 8 aortas per genotype). C, High-magnification DIC images of microvessel sprouts in WT and CIB1−/− tibialis anterior muscle sections cultured in growth media for 8 days (performed in at least duplicates, n=3 per genotype). Scale bar, 100 μm. D, Representative images of growth factor-reconstituted Matrigel plugs subcutaneously injected in WT and CIB1−/− mice. Newly formed microvessels are indicated by arrowheads. Scale bar, 25 μm. E, Quantification of microvessels infiltrating untreated or growth factor-reconstituted Matrigel plugs from WT and CIB1−/− mice. Error bars represent SEM (n=3 to 7 plugs per group). *P<0.05, **P<0.001.

CIB1 Deficiency Leads to Decreased Oxygen-Induced Retinal Angiogenesis

Mice lacking CIB1 develop and reach adult reproductive age normally.17 Therefore, not surprisingly, we observed that developmental retinal angiogenesis in CIB1−/− mice proceeds normally (supplemental Figure V). However, because CIB1 appeared to be a critical regulator of EC function and signaling, we hypothesized that CIB1−/− mice may still have a defect in pathological retinal angiogenesis. To test this, we examined CIB1−/− mice using an oxygen-induced retinal angiogenesis assay, wherein in vivo exposure to an elevated inspired oxygen concentration obliterates the central retinal capillaries, leading to hypoxia in the mouse neonatal retina. Subsequent return to normoxia induces exuberant angiogenesis, resulting in formation of aberrant capillary neovessel buds that can be visualized in isolectin GSL-1-B4–stained retinal flat mounts.20,28

Well-defined buds were detected in WT P17 flat mounted retinas. In CIB1−/− retinas, fewer and less clearly defined buds were evident (Figure 4A and 4B). Because these buds are composed of clusters of tortuous vessels that protrude through the retinal ILM,29 retinal cross-sections were obtained to assess the size and morphology of these neovessels. WT retinal cross-sections displayed large protruding microvessels that occasionally ruptured through the ILM, whereas CIB1−/− retinal cross-sections showed blood vessels directly under the ILM that were smaller in size and did not protrude through as frequently (Figure 4C and 4D). In CIB1−/− retinas, the ILM was also almost always intact (Figure 4C). Therefore, these data provide the first evidence demonstrating that CIB1−/− mice have impaired pathological angiogenesis in response to ischemia.

Figure4
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 4. Oxygen-induced retinal neovascularization is decreased in CIB1−/− mice. A, Isolectin GSL1–B4–stained flat mounted retinas from WT and CIB1−/− neonatal mice exposed to hyperoxic conditions followed by normoxia (left images). Vascular buds formed in WT and CIB1−/− ischemic retinas are indicated by arrowheads in magnified retinal areas (right images). Scale bar, 25 μm. B, Quantification of vascular buds per retina in WT and CIB1−/− mice (n=8 per mouse genotype). C, Representative H&E-stained cross-sections from WT and CIB1−/− retinas after exposure to hyperoxia, followed by normoxia. The WT retina shows microvessel protrusion (☆) and rupture (arrow) through the ILM. Scale bar, 50 μm. D, Quantification of mean capillary area of microvessels directly under the ILM in WT and CIB1−/− retinas following ischemic injury (n=4 mice for each mouse genotype). V indicates vitreous; GCL, ganglion cell layer; IPL, inner plexiform layer. Error bars represent SEM. *P<0.05.

CIB1 Deficiency Delays Postischemic Recovery and Neovascularization

A common mouse model for peripheral vascular disease is experimentally induced hindlimb ischemia through unilateral femoral artery ligation.22 In this model, blood flow to the hindlimb is effectively eliminated, which rapidly induces ischemia and postischemic recovery mechanisms (ie, adaptive angiogenesis and arteriogenesis).30 To extend our observations from the oxygen-induced retinal angiogenesis assay, we performed this assay to determine whether CIB1 also plays a role in adaptive ischemia-induced angiogenesis.

Noninvasive, laser-scanning Doppler velocimetry22 demonstrated that by 14 days postfemoral artery ligation, 90% of hindpaw plantar region perfusion was restored in WT mice but only 60% in CIB1−/− mice (Figure 5A and 5B). Furthermore, ischemic tissue injury was more severe in CIB1−/− mice, as assessed by appearance and use scores.23 Incidence of nail and toe discoloration, toe loss, hindpaw cyanosis, as well as impaired hindlimb function were several fold higher in CIB1−/− mice relative to WT littermates (Figure 5C and 5D). Similarly, increased atrophy and fibrosis were observed in the gastrocnemius muscles of CIB1−/− hindlimbs, which are known to experience substantial ischemia immediately after femoral artery ligation (Figure 6A).22 Average muscle fiber size in CIB1−/− ischemic gastrocnemius muscles was reduced by 23%, compared with only 6% in WT muscles (Figure 6B), indicating that CIB1−/− tissue experiences more profound tissue damage after ischemia.

Figure5
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 5. Reduced perfusion and recovery in CIB1−/− mouse ischemic hindpaws and hindlimbs following femoral artery ligation. A, Representative laser-scanning Doppler perfusion images of the ventral hindpaw surfaces of the same ischemic hindlimbs of a single WT and CIB1−/− mouse, performed in a blinded manner. Relative flow velocity is indicated by 6-hue pseudocolor, in which gray represents 0 and white represents maximal velocity (range of velocity values, 0 to 5000 perfusion units [PU], arbitrary units). Preligation relative blood flow velocity is high in both groups, as indicated by white and red. One day after ligation, blood flow is largely eliminated to the hindpaw, as indicated by blue. Evidence of toe gangrene is observed in CIB1−/− mouse ischemic hindpaws by 7 days. B, Quantification of perfusion at 7, 14, and 21 days after femoral artery ligation in WT and CIB1−/− mice (n=11 per genotype; *P<0.05, **P<0.001). C and D, Hindpaw appearance and hindlimb use scores were determined to assess rates of recovery in WT and CIB1−/− mice (n=11 per genotype). Mann–Whitney U test: *P<0.05, **P<0.01. Error bars represent ±SEM.

Figure6
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 6. Tissue atrophy and reduced angiogenesis in CIB1−/− mouse ischemic gastrocnemius muscle. A, Contrast-enhanced H&E and Masson’s trichrome (MT)-stained sections of WT and CIB1−/− ischemic and nonischemic hindlimb gastrocnemius muscles. B, Mean muscle fiber size (μm2) per muscle fascicle in ischemic and nonischemic gastrocnemius muscles from WT and CIB1−/− mice. C, PAK1 activity, ERK1/2, and p38 phosphorylation levels in WT and CIB1−/− ischemic (I) and nonischemic (NI) gastrocnemius muscle tissue lysates isolated from the same mouse 4 days after unilateral femoral artery ligation. Western blots of total PAK1, total ERK1/2, p38, Rac, and Coomassie stain of myelin basic protein (MBP) serve as loading controls. D, Isolectin GSL1–B4–staining pattern of capillary EC in WT and CIB1−/−, ischemic and nonischemic gastrocnemius muscles. Scale bars, 50 μm. E, Quantification of microvessel density, expressed as the ratio of capillary number-to-muscle fiber number per fascicle in WT and CIB1−/− mice. Error bars represent SEM (n=5 to 9 per genotype). *P<0.05.

Interestingly, tissue homogenates of CIB1−/− ischemic gastrocnemius muscles, isolated 4 days after femoral artery ligation showed a significant decrease in PAK1 activation and ERK1/2 phosphorylation (Figure 6C). ERK1/2 phosphorylation in CIB1−/− nonischemic gastrocnemius muscle tissue was also significantly reduced. However, no consistent differences were detected in p38 phosphorylation and MMP-2 expression between WT and CIB1−/− ischemic and nonischemic gastrocnemius muscles (Figure 6C). Thus, these data correlate with our findings in vitro and demonstrate that CIB1−/− mice have a specific defect in PAK1 and ERK1/2 signaling, which likely contributes to the decrease in recovery in CIB1−/− ischemic tissue.

Attenuated PAK1 activation may also lead to decreased angiogenesis, which could also explain the observed increase in tissue damage in CIB1−/− mice following femoral artery ligation.24 To test this, we determined capillary densities in gastrocnemius muscles 21 days after femoral artery ligation in WT and CIB1−/− mice. Isolectin GSL-1-B4 staining revealed an increase in capillary density only in WT ischemic gastrocnemius muscles (Figure 6D and 6E), thus providing further evidence of reduced ischemia-induced angiogenesis in CIB1−/− mice. Because postmortem x-ray angiography revealed unaltered arteriogenesis in CIB1−/− mice (unpublished data, 2007), this defect in ischemia-induced angiogenesis appears to be specific.

Discussion

CIB1 is an important regulatory molecule that is expressed in different tissue types and has various binding partners.11–14 However, the role of CIB1 in ECs has never been explored. In this study, we use in vitro, ex vivo, and in vivo complementary analyses to provide the first evidence describing the critical role of CIB1 in EC function and signaling, growth factor–induced angiogenesis, and ischemia-induced pathological and adaptive angiogenesis.

Recent evidence suggests that CIB1 contributes to important intracellular signaling mechanisms. For example, we previously demonstrated that CIB1 binds to and activates PAK1 in different cell types and that CIB1 depletion results in decreased PAK1 activation on adhesion to fibronectin.14 Furthermore, we previously observed a Cdc42-dependent upregulation of PAK1 activity in CIB1-depeletd rat embryo fibroblasts with extended adhesion to fibronectin.14 In agreement with this, we also observed significantly reduced adhesion-induced PAK1 activation in CIB1−/− ECs. However, we did not detect a similar rebound of PAK1 activation with prolonged adhesion to fibronectin (up to 180 minutes) in CIB1−/− ECs, suggesting that this mechanism is either not as profound in ECs or occurs at later time points. More importantly, we found that PAK1 activation in vivo is dramatically reduced in CIB1−/− ischemic gastrocnemius muscle tissue homogenates. To our knowledge, this finding provides the first evidence demonstrating CIB1-dependent PAK1 activation in vivo and also suggests a role for PAK1 in ischemia-induced angiogenesis. Thus, these results reveal a functional interaction between CIB1 and PAK1 in multiple cell types and tissues.

Moreover, we previously demonstrated that CIB1 depletion increases fibroblast and epithelial cell migration.14 However, the present study demonstrates the opposite result, in which CIB1-depleted and CIB1−/− ECs exhibited decreased migration. These apparent differences may be attributable to a number of factors such as differences in cell types, activated signaling mechanisms, and/or experimental conditions. For example, the CIB1-binding partner PAK1 has been shown to both increase and decrease migration through different signaling pathways.25 In addition, experimental conditions used in this study were different than what was described previously (haptotactic migration in this study was toward 25 μg/mL fibronectin versus 5 μg/mL fibronectin14), which may significantly affect the migratory response.31

Previous reports also demonstrate that VEGF and bFGF can rapidly induce PAK activation,24 which in turn can phosphorylate and activate MEK132 and the MAPKs ERK1/233 and p38.34 Here we demonstrate that both PAK1 and ERK1/2 activation were significantly decreased in CIB1−/− ECs and CIB1−/− mouse nonischemic and ischemic gastrocnemius muscles. These defects appear to be specific because no profound differences were detected in the activation state of other kinases such as FAK, protein kinase C, and p38 MAPK. Moreover, the loss of CIB1 in part mimics the angiogenic defects observed when ERK1/2 is pharmacologically inhibited in vivo.35 Thus, it is likely that attenuated PAK1 and ERK1/2 activation contributes to the decrease in CIB1−/− ECs growth factor–induced functions, as well as microvessel formation in ex vivo CIB1−/− organ cultures and in vivo Matrigel plugs.

Additionally, ERK1/2 activation is necessary for transcriptional upregulation of MMPs,26 which are key modulators of pathophysiological events.27 Constitutively expressed by various cell types (including ECs), MMP-2 is known to contribute to pathological angiogenesis, including ischemia-induced retinal angiogenesis.36 Its contributions to angiogenesis are mediated by extracellular matrix degradation and proteolytic activation of other MMPs, such as proMMP-9, which is also essential in ischemia-induced angiogenesis.27 Accordingly, genetic deletion of MMP-2 and MMP-9 significantly reduces postnatal ischemia-induced angiogenesis.37,38 Here we report a similar phenotype in CIB1−/− mice and that CIB1−/− ECs generate less MMP-2. Thus, it is most likely that the defect in MMP-2 expression and secretion contributes to the blunted angiogenic response observed in CIB1−/− ischemic retinas and hindlimb gastrocnemius muscles.

Although CIB1−/− mice exhibit impaired ischemia-induced angiogenesis, they undergo normal developmental and physiological angiogenesis (developing retinal vasculature and female reproduction are normal). Although CIB1 homologs such as CIB2, CIB3, and CIB4 might compensate for the loss of CIB1, it is more likely that CIB1 is a member of a growing group of genes that contributes to pathological angiogenesis during ischemia, inflammation, and tumor growth but not embryonic vasculogenesis and developmental angiogenesis.39 Prominent examples of these include knockout mice for bFGF,40 intercellular adhesion molecule 2,18 prostaglandin E2 receptor,41 and integrins β3 and β5.20

Collectively, our study identifies a previously uncharacterized role for CIB1 in the vasculature and for the first time demonstrates that it has a role in angiogenesis in vivo. Our study also demonstrates that CIB1 is critical in ischemia-induced pathological angiogenesis in the retina, as well as ischemia-induced adaptive angiogenesis in the hindlimb. However, CIB1 is not essential for developmental angiogenesis. Therefore, our studies identify CIB1 as a novel target for both pro- and antiangiogenic therapy.

Acknowledgments

We thank D. Baltimore for the lentiviral FG-12 vectors; R. Auerbach and C. Patterson for MECs and bovine aortic ECs, respectively; J. Ferguson for Northern blotting assistance; S. Holly for R-Ras shRNA sequence; M. Rojas and colleagues for assistance with femoral artery ligations; J. McColm and P. Geisen for assistance with hyperoxic chamber; K. Vadali for assistance with FAK blotting, K. McNaughton and colleagues for assistance with tissue sectioning and staining; and the University of North Carolina at Chapel Hill Michael Hooker Microscopy Facility for imaging assistance.

Sources of Funding

This work was supported by NIH grants 2-P01-HL45100 (to L.V.P.), HL-62584 (to J.E.F.), R01 EY15130 (to M.E.H.), and T32-HL-069768 (to M.A.Z.).

Disclosures

None.

Footnotes

  • Original received June 9, 2007; revision received September 17, 2007; accepted October 20, 2007.

References

  1. ↵
    Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003; 9: 653–660.
    OpenUrlCrossRefPubMed
  2. ↵
    Ferris FL III, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984; 102: 1640–1642.
    OpenUrlCrossRefPubMed
  3. ↵
    Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994; 331: 1480–1487.
    OpenUrlCrossRefPubMed
  4. ↵
    Gariano RF, Gardner TW. Retinal angiogenesis in development and disease. Nature. 2005; 438: 960–966.
    OpenUrlCrossRefPubMed
  5. ↵
    Ng YS, D’Amore PA. Therapeutic angiogenesis for cardiovascular disease. Curr Control Trials Cardiovasc Med. 2001; 2: 278–285.
    OpenUrlCrossRefPubMed
  6. ↵
    Folkman J. Angiogenesis and breast cancer. J Clin Oncol. 1994; 12: 441–443.
    OpenUrlPubMed
  7. ↵
    Pepper MS. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol. 2001; 21: 1104–1117.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    Naik UP, Patel PM, Parise LV. Identification of a novel calcium-binding protein that interacts with the integrin alphaIIb cytoplasmic domain. J Biol Chem. 1997; 272: 4651–4654.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    Yuan W, Leisner TM, McFadden AW, Wang Z, Larson MK, Clark S, Boudignon-Proudhon C, Lam SC, Parise LV. CIB1 is an endogenous inhibitor of agonist-induced integrin alphaIIbbeta3 activation. J Cell Biol. 2006; 172: 169–175.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Shock DD, Naik UP, Brittain JE, Alahari SK, Sondek J, Parise LV. Calcium-dependent properties of CIB binding to the integrin alphaIIb cytoplasmic domain and translocation to the platelet cytoskeleton. Biochem J. 1999; 342 Pt 3: 729–735.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    Stabler SM, Ostrowski LL, Janicki SM, Monteiro MJ. A myristoylated calcium-binding protein that preferentially interacts with the Alzheimer’s disease presenilin 2 protein. J Cell Biol. 1999; 145: 1277–1292.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    White C, Yang J, Monteiro MJ, Foskett JK. CIB1, a ubiquitously expressed Ca2+-binding protein ligand of the InsP3 receptor Ca2+ release channel. J Biol Chem. 2006; 281: 20825–20833.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    Naik MU, Naik UP. Calcium- and integrin-binding protein regulates focal adhesion kinase activity during platelet spreading on immobilized fibrinogen. Blood. 2003; 102: 3629–3636.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    Leisner TM, Liu M, Jaffer ZM, Chernoff J, Parise LV. Essential role of CIB1 in regulating PAK1 activation and cell migration. J Cell Biol. 2005; 170: 465–476.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    Kiosses WB, Hood J, Yang S, Gerritsen ME, Cheresh DA, Alderson N, Schwartz MA. A dominant-negative p65 PAK peptide inhibits angiogenesis. Circ Res. 2002; 90: 697–702.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    Shen TL, Park AY, Alcaraz A, Peng X, Jang I, Koni P, Flavell RA, Gu H, Guan JL. Conditional knockout of focal adhesion kinase in endothelial cells reveals its role in angiogenesis and vascular development in late embryogenesis. J Cell Biol. 2005; 169: 941–952.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    Yuan W, Leisner TM, McFadden AW, Clark S, Hiller S, Maeda N, O’Brien DA, Parise LV. CIB1 is essential for mouse spermatogenesis. Mol Cell Biol. 2006; 26: 8507–8514.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Huang MT, Mason JC, Birdsey GM, Amsellem V, Gerwin N, Haskard DO, Ridley AJ, Randi AM. Endothelial intercellular adhesion molecule (ICAM)-2 regulates angiogenesis. Blood. 2005; 106: 1636–1643.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    Nicosia RF, Ottinetti A. Growth of microvessels in serum-free matrix culture of rat aorta. A quantitative assay of angiogenesis in vitro. Lab Invest. 1990; 63: 115–122.
    OpenUrlPubMed
  20. ↵
    Reynolds LE, Wyder L, Lively JC, Taverna D, Robinson SD, Huang X, Sheppard D, Hynes RO, Hodivala-Dilke KM. Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat Med. 2002; 8: 27–34.
    OpenUrlCrossRefPubMed
  21. ↵
    Herve MA, Buteau-Lozano H, Mourah S, Calvo F, Perrot-Applanat M. VEGF189 stimulates endothelial cells proliferation and migration in vitro and up-regulates the expression of Flk-1/KDR mRNA. Exp Cell Res. 2005; 309: 24–31.
    OpenUrlCrossRefPubMed
  22. ↵
    Chalothorn D, Zhang H, Clayton JA, Thomas SA, Faber JE. Catecholamines augment collateral vessel growth and angiogenesis in hindlimb ischemia. Am J Physiol Heart Circ Physiol. 2005; 289: H947–H959.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    Stabile E, Burnett MS, Watkins C, Kinnaird T, Bachis A, la Sala A, Miller JM, Shou M, Epstein SE, Fuchs S. Impaired arteriogenic response to acute hindlimb ischemia in CD4-knockout mice. Circulation. 2003; 108: 205–210.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    Hood JD, Frausto R, Kiosses WB, Schwartz MA, Cheresh DA. Differential alphav integrin-mediated Ras-ERK signaling during two pathways of angiogenesis. J Cell Biol. 2003; 162: 933–943.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    Vadlamudi RK, Kumar R. P21-activated kinases in human cancer. Cancer Metastasis Rev. 2003; 22: 385–393.
    OpenUrlCrossRefPubMed
  26. ↵
    Boyd PJ, Doyle J, Gee E, Pallan S, Haas TL. MAPK signaling regulates endothelial cell assembly into networks and expression of MT1-MMP and MMP-2. Am J Physiol Cell Physiol. 2005; 288: C659–C668.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    Bjorklund M, Koivunen E. Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta. 2005; 1755: 37–69.
    OpenUrlPubMed
  28. ↵
    Smith LE, Wesolowski E, McLellan A, Kostyk SK, D’Amato R, Sullivan R, D’Amore PA. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci. 1994; 35: 101–111.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    Zhang S, Leske DA, Holmes JM. Neovascularization grading methods in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2000; 41: 887–891.
    OpenUrlAbstract/FREE Full Text
  30. ↵
    Heil M, Eitenmuller I, Schmitz-Rixen T, Schaper W. Arteriogenesis versus angiogenesis: similarities and differences. J Cell Mol Med. 2006; 10: 45–55.
    OpenUrlCrossRefPubMed
  31. ↵
    Palecek SP, Loftus JC, Ginsberg MH, Lauffenburger DA, Horwitz AF. Integrin-ligand binding properties govern cell migration speed through cell-substratum adhesiveness. Nature. 1997; 385: 537–540.
    OpenUrlCrossRefPubMed
  32. ↵
    Slack-Davis JK, Eblen ST, Zecevic M, Boerner SA, Tarcsafalvi A, Diaz HB, Marshall MS, Weber MJ, Parsons JT, Catling AD. PAK1 phosphorylation of MEK1 regulates fibronectin-stimulated MAPK activation. J Cell Biol. 2003; 162: 281–291.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    Beeser A, Jaffer ZM, Hofmann C, Chernoff J. Role of group A p21-activated kinases in activation of extracellular-regulated kinase by growth factors. J Biol Chem. 2005; 280: 36609–36615.
    OpenUrlAbstract/FREE Full Text
  34. ↵
    Dechert MA, Holder JM, Gerthoffer WT. p21-activated kinase 1 participates in tracheal smooth muscle cell migration by signaling to p38 Mapk. Am J Physiol Cell Physiol. 2001; 281: C123–C132.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    Eliceiri BP, Klemke R, Stromblad S, Cheresh DA. Integrin alphavbeta3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis. J Cell Biol. 1998; 140: 1255–1263.
    OpenUrlAbstract/FREE Full Text
  36. ↵
    Ohno-Matsui K, Uetama T, Yoshida T, Hayano M, Itoh T, Morita I, Mochizuki M. Reduced retinal angiogenesis in MMP-2-deficient mice. Invest Ophthalmol Vis Sci. 2003; 44: 5370–5375.
    OpenUrlAbstract/FREE Full Text
  37. ↵
    Johnson C, Sung HJ, Lessner SM, Fini ME, Galis ZS. Matrix metalloproteinase-9 is required for adequate angiogenic revascularization of ischemic tissues: potential role in capillary branching. Circ Res. 2004; 94: 262–268.
    OpenUrlAbstract/FREE Full Text
  38. ↵
    Cheng XW, Kuzuya M, Nakamura K, Maeda K, Tsuzuki M, Kim W, Sasaki T, Liu Z, Inoue N, Kondo T, Jin H, Numaguchi Y, Okumura K, Yokota M, Iguchi A, Murohara T. Mechanisms underlying the impairment of ischemia-induced neovascularization in matrix metalloproteinase 2-deficient mice. Circ Res. 2007; 100: 904–913.
    OpenUrlAbstract/FREE Full Text
  39. ↵
    Gentry HR, Singer AU, Betts L, Yang C, Ferrara JD, Sondek J, Parise LV. Structural and biochemical characterization of CIB1 delineates a new family of EF-hand-containing proteins. J Biol Chem. 2005; 280: 8407–8415.
    OpenUrlAbstract/FREE Full Text
  40. ↵
    Dono R, Texido G, Dussel R, Ehmke H, Zeller R. Impaired cerebral cortex development and blood pressure regulation in FGF-2-deficient mice. EMBO J. 1998; 17: 4213–4225.
    OpenUrlAbstract
  41. ↵
    Kamiyama M, Pozzi A, Yang L, DeBusk LM, Breyer RM, Lin PC. EP2, a receptor for PGE2, regulates tumor angiogenesis through direct effects on endothelial cell motility and survival. Oncogene. 2006; 25: 7019–7028.
    OpenUrlCrossRefPubMed
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Circulation Research
November 26, 2007, Volume 101, Issue 11
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Tables
  • Supplemental Materials
  • Info & Metrics

Article Tools

  • Print
  • Citation Tools
    CIB1 Regulates Endothelial Cells and Ischemia-Induced Pathological and Adaptive Angiogenesis
    Mohamed A. Zayed, Weiping Yuan, Tina M. Leisner, Dan Chalothorn, Andrew W. McFadden, Michael D. Schaller, M. Elizabeth Hartnett, James E. Faber and Leslie V. Parise
    Circulation Research. 2007;101:1185-1193, originally published November 26, 2007
    https://doi.org/10.1161/CIRCRESAHA.107.157586

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  •  Download Powerpoint
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Circulation Research.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    CIB1 Regulates Endothelial Cells and Ischemia-Induced Pathological and Adaptive Angiogenesis
    (Your Name) has sent you a message from Circulation Research
    (Your Name) thought you would like to see the Circulation Research web site.
  • Share on Social Media
    CIB1 Regulates Endothelial Cells and Ischemia-Induced Pathological and Adaptive Angiogenesis
    Mohamed A. Zayed, Weiping Yuan, Tina M. Leisner, Dan Chalothorn, Andrew W. McFadden, Michael D. Schaller, M. Elizabeth Hartnett, James E. Faber and Leslie V. Parise
    Circulation Research. 2007;101:1185-1193, originally published November 26, 2007
    https://doi.org/10.1161/CIRCRESAHA.107.157586
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Subjects

  • Genetics
    • Genetically Altered and Transgenic Models
  • Basic, Translational, and Clinical Research
    • Ischemia
    • Endothelium/Vascular Type/Nitric Oxide
    • Angiogenesis

Circulation Research

  • About Circulation Research
  • Editorial Board
  • Instructions for Authors
  • Abstract Supplements
  • AHA Statements and Guidelines
  • Permissions
  • Reprints
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
3355 Keswick Rd
Main Bldg 103
Baltimore, MD 21211
CircRes@circresearch.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured